The purpose of this study was to determine whether florbetapir PET would detect amyloid deposition in AD and DLB patients, and whether florbenazine PET would identify decreased VMAT2 density in PD and DLB patients. This evidence concerns the gene SLC18A2 and Lewy body dementia.